厄洛替尼,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
851	TT	Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to erlotinib.
850	CT	Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.
849	CC	Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.

等位基因

注释文本

Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to erlotinib.

850

Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.

849

Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.

id	证据的ID	总结
146	981475801	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.
145	981475378	Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.
144	981475352	Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.
143	981475337	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.
142	981475298	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.
141	981475286	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.
140	981475253	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.
139	981475241	Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.
138	981417766	Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.
137	981417754	Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.
136	1447673749	Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.

证据的ID

总结

146

981475801

Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Adenocarcinoma as compared to allele C.

145

981475378

Allele T is associated with increased acquired resistance when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.

144

981475352

Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.

143

981475337

Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.

142

981475298

Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.

141

981475286

Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.

140

981475253

Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.

139

981475241

Allele T is associated with increased acquired resistance to EGFR inhibitors when treated with erlotinib or gefitinib in advanced non-small-cell lung cancer patients as compared to allele C.

138

981417766

Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.

137

981417754

Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.

136

1447673749

Allele T is associated with Drug Resistance when treated with erlotinib or gefitinib in people with Lung Neoplasms as compared to allele C.

id	类型	评论
1273	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1272	Update	Edited phenotype descriptions and added phenotype tags.
1271	Update	Restricted to erlotinib. Updated to new format.

类型

1273

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1272

Update

Edited phenotype descriptions and added phenotype tags.

1271

Update

Restricted to erlotinib. Updated to new format.